Company news
Aquestive Therapeutics, Inc. news in 2020
Aquestive Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer
December 15, 2020
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization
November 22, 2020
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
November 17, 2020
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 3, 2020
Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million
November 2, 2020
Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8: 00 a.m. ET
October 13, 2020
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters
September 24, 2020
Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis
August 19, 2020
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis
August 9, 2020
Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches
August 3, 2020
Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
July 27, 2020
Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8: 00 a.m. ET
July 14, 2020
Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
June 28, 2020
Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
June 15, 2020
Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders
June 3, 2020
Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA Approval
May 20, 2020
Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
May 6, 2020
Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track
May 4, 2020
Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6
April 20, 2020
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
March 10, 2020
Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020
February 19, 2020
Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film
February 9, 2020
Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
February 5, 2020
Aquestive Therapeutics Receives FDA Response to Citizen’s Petition
January 11, 2020
Aquestive Therapeutics Exceeds Top End of Guidance Range for Preliminary Unaudited Full Year 2019 Total Revenues and Provides Initial Full Year 2020 Guidance
January 9, 2020
Calls in 2020
Decks in 2020
- Corporate Update (September 2020)
Corporate update · 5 slides · Sep 25, 2020